OncBioMune reports additional Phase I data for prostate cancer vaccine

OncBioMune Pharmaceuticals Inc. (OTCQB:OBMP) reported additional data from 14 evaluable patients with hormone-naïve and hormone-independent recurrent prostate cancer

Read the full 180 word article

User Sign In